Impella 5.5 首次人体评估:德国 CE 认证后早期经验
该研究评估了德国六家机械循环支持中心在 CE 认证后首批连续 46 例患者中使用新型 Impella 5.5 的早期结果。主要终点为 30 天和 90 天全因死亡率,分别为 73.9% 和 71.7% 生存率。装置相关不良事件包括泵血栓、出血和套管移位,但无主动脉瓣损伤,提示短期结局良好。
要点
- Impella 5.5 在急性心力衰竭患者中 30 天生存率 73.9%,90 天生存率 71.7%。
- 34.8% 患者心肌恢复撤机,41.3% 桥接至持久装置。
- 泵血栓发生率 15.2%,出血需输血 34.8%,套管移位 21.7%。
核心结论
- Impella 5.5 首版在急性心力衰竭患者中呈现有希望的早期结局,不良事件谱对短期装置有利。
研究设计与样本
- 研究为首次人体系列评估,纳入 2018 年 3 月至 2019 年 9 月德国六家高容量机械循环支持中心连续 46 例患者。
- 主要终点为 30 天和 90 天全因死亡率。
主要发现
- 患者平均年龄 59.0 ± 11.5 岁,43 例(93.4%)为男性。
- 主要适应证为缺血性心肌病和急性心肌梗死(47.8%)。
- 平均支持时间 15.5 ± 24.2 天(范围 0-164,中位数 10 天,IQR 7-19),总支持患者日 712 天。
- 30 天和 90 天生存率分别为 73.9%(95% CI: 63.3-88.9%)和 71.7%(95% CI: 60.7-87.1%)。
- 16 例(34.8%)心肌恢复撤机,19 例(41.3%)桥接至持久装置;15 例(32.6%)可坐椅,15 例(32.6%)可步行。
关键数值与推荐
- 仅发生 1 例卒中,无其他血栓栓塞并发症,未观察到主动脉瓣损伤。
- 7 例(15.2%)泵血栓,9 例(19.6%)装置交换,16 例(34.8%)出血需输血,10 例(21.7%)流入套管移位至主动脉根部。
临床怎么用
- Impella 5.5 可用于急性心力衰竭患者的短期循环支持,需警惕泵血栓、出血和套管移位。
- 随着经验积累,使用指征可能扩展至其他心脏休克病因,或改善心肌恢复和生存。
局限性
- 研究为首次人体系列,样本量有限(46 例),随访时间短,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Abiomed Impella 5.5 (Danvers, MA) is a newly developed axial flow transaortic cardiac support device mounted on a 9 Fr steering catheter with a 21 Fr pump cannula. Impella 5.5 is intended for longer use and was approved for 30 days in 2018. This study evaluated the first-in-man series at six high-volume mechanical circulatory support centers in Germany after CE approval. METHODS: The first 46 consecutive patients worldwide underwent implantation in six German centers between March 2018 and September 2019 for post-CE approval evaluation. The primary end-point was 30 days and 90 days all-cause mortality. RESULTS: The mean age of patients was 59.0 ± 11.5 years, and 43 (93.4%) were men. Half of the patients had acute on chronic heart failure. The main indication for Impella 5.5 implantation was ischemic cardiomyopathy and acute myocardial infarction (47.8%). The mean support time was 15.5 ± 24.2 days (range 0-164, median 10 days (IQR = 7-19)) with a total of 712 patient-days on support. The 30 days and 90 days survival rates were 73.9% (95% CI: 63.3-88.9%) and 71.7% (95% CI: 60.7-87.1%), respectively. Additionally, 16 patients (34.8%) were weaned from the device for native heart recovery, and 19 (41.3%) were bridged to a durable device. Fifteen patients (32.6%) were mobilized to a chair, and 15 (32.6%) were ambulatory. We only noted one stroke and found no other thromboembolic complications. No aortic valve damage was observed in the study cohort. Finally, seven patients (15.2 %) had pump thrombosis, and nine (19.6 %) underwent device exchange. Sixteen patients (34.8 %) suffered from bleeding requiring transfusions during the whole treatment course. In ten patients (21.7%), the inflow cannula dislocated into the aortic root. CONCLUSIONS: The first version of the Impella 5.5 presents promising early outcomes for patients with acute heart failure and expands the spectrum of available devices. The adverse event profile is favorable for short-term devices. Dislocations have been addressed by design changes. With increasing experience with this device, our study suggests that the indications for use will expand to other cardiac shock etiologies and may improve myocardial recovery and survival in patients with cardiogenic shock.
引用
- Bernhardt AM, Potapov E, Schibilsky D, et al. First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany. J Heart Lung Transplant. 2021. PMID: 34030970. doi:10.1016/j.healun.2021.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。